Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Sunshine Biopharma (SBFM) Depreciation & Amortization (IS) (2016 - 2024)

Sunshine Biopharma's Depreciation & Amortization (IS) history spans 7 years, with the latest figure at $42618.0 for Q1 2024.

  • For Q1 2024, Depreciation & Amortization (IS) rose 22.78% year-over-year to $42618.0; the TTM value through Mar 2024 reached $83911.0, up 87.69%, while the annual FY2025 figure was $332070.0, 48.56% up from the prior year.
  • Depreciation & Amortization (IS) reached $42618.0 in Q1 2024 per SBFM's latest filing, up from $34710.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (IS) ranged from a high of $42618.0 in Q1 2024 to a low of $3110.0 in Q1 2022.
  • Average Depreciation & Amortization (IS) over 3 years is $26812.7, with a median of $34710.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (IS): soared 1016.08% in 2023, then rose 22.78% in 2024.
  • A 3-year view of Depreciation & Amortization (IS) shows it stood at $3110.0 in 2022, then skyrocketed by 1016.08% to $34710.0 in 2023, then increased by 22.78% to $42618.0 in 2024.
  • Per Business Quant, the three most recent readings for SBFM's Depreciation & Amortization (IS) are $42618.0 (Q1 2024), $34710.0 (Q1 2023), and $3110.0 (Q1 2022).